Literature DB >> 25195735

The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.

Katy Teo1, Valerie G Brunton1.   

Abstract

ATX (autotaxin) is a secreted lysophospholipase capable of catalysing the formation of the bioactive lipid mediator LPA (lysophosphatidate) from LPC (lysophosphatidylcholine). The ATX-LPA signalling axis plays an important role in both normal physiology and disease pathogenesis, including cancer. In a number of different human cancers, expression of ATX and the G-protein-coupled LPARs (lysophosphatidic acid receptors) have been shown to be elevated and their activation regulates many processes central to tumorigenesis, including proliferation, invasion, migration and angiogenesis. The present review provides an overview of the ATX-LPA signalling axis and collates current knowledge regarding its specific role in breast cancer. The potential manipulation of this pathway to facilitate diagnosis and treatment is also discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25195735     DOI: 10.1042/BJ20140680

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  10 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 2.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

3.  Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate.

Authors:  Matthew G K Benesch; Yuan Y Zhao; Jonathan M Curtis; Todd P W McMullen; David N Brindley
Journal:  J Lipid Res       Date:  2015-04-20       Impact factor: 5.922

4.  The expressions of autotaxin-lysophosphatidate signaling-related proteins in metastatic breast cancer.

Authors:  Su Jung Shim; Eunah Shin; Choong-Sik Lee; Ja Seung Koo
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

5.  Type I Interferons Function as Autocrine and Paracrine Factors to Induce Autotaxin in Response to TLR Activation.

Authors:  Jianwen Song; Ming Guan; Zhenwen Zhao; Junjie Zhang
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

Review 6.  Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo.

Authors:  Matthew G K Benesch; Xiaoyun Tang; Ganesh Venkatraman; Raie T Bekele; David N Brindley
Journal:  J Biomed Res       Date:  2015-08-28

Review 7.  Hepatitis C virus-associated pruritus: Etiopathogenesis and therapeutic strategies.

Authors:  Youssef Alhmada; Denis Selimovic; Fadi Murad; Sarah-Lilly Hassan; Youssef Haikel; Mossaad Megahed; Matthias Hannig; Mohamed Hassan
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

8.  ENPP2 Promoter Methylation Correlates with Decreased Gene Expression in Breast Cancer: Implementation as a Liquid Biopsy Biomarker.

Authors:  Maria Panagopoulou; Andrianna Drosouni; Dionysiοs Fanidis; Makrina Karaglani; Ioanna Balgkouranidou; Nikolaos Xenidis; Vassilis Aidinis; Ekaterini Chatzaki
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

9.  Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.

Authors:  Valentina Zuckerman; Eugene Sokolov; Jacob H Swet; William A Ahrens; Victor Showlater; David A Iannitti; Iain H Mckillop
Journal:  Oncotarget       Date:  2016-01-19

10.  Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival.

Authors:  Kyung-Hee Kim; Jungnam Joo; Boram Park; Sang-Jae Park; Woo Jin Lee; Sung-Sik Han; Tae Hyun Kim; Eun Kyung Hong; Sang Myung Woo; Byong Chul Yoo
Journal:  Oncotarget       Date:  2017-11-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.